Latest Breaking News On - Neeta somaiah - Page 1 : vimarsana.com

Presurgical Immunotherapy May Improve Survival in Certain Sarcomas

Treatment with immunotherapy demonstrated positive results regarding survival in patients with two types of soft-tissue sarcomas, research found.

United statesChristina rolandNeeta somaiahUniversity of texas md anderson cancer centerMd anderson cancer centerNational cancer instituteNature cancerClinical trialsCancer center

Pre-Surgery Immunotherapy Boosts Long-Term Sarcoma Survival

Pre-Surgery Immunotherapy Boosts Long-Term Sarcoma Survival
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesNeeta somaiahChristina rolandAmerican society of clinical oncologyBristol myers squibbUniversity of texas md anderson cancer centerNature cancerSarcoma medicalClinical oncologyBristol myers

Immunotherapy before surgery leads to promising long-term survival in sarcoma patients

Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising l

United statesChristina rolandNeeta somaiahUniversity of texasAmerican society of clinical oncologyAnderson cancer centerBristol myers squibbNature cancerManderson cancerSarcoma medicalClinical oncologyBristol myersOft tissue sarcoma immunotherapy cancer researchAll journal newsMbargoed feed hiddenAture journal

Clinical trial shows immunotherapy before surgery leads to promising long-term survival in sarcoma patients

Clinical trial shows immunotherapy before surgery leads to promising long-term survival in sarcoma patients
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesChristinal rolandChristina rolandNeeta somaiahUniversity of texas md anderson cancer centerNature cancerSarcoma medical

Bezuclastinib/Sunitinib Combination Under Evaluation in Advanced GIST

The TKI bezuclastinib plus standard-of-care sunitinib may become the new second-line standard treatment for patients with gastrointestinal stromal tumor that has progressed on imatinib.

City ofUnited kingdomUnited statesRobin jonesNeeta somaiahDepartment of sarcoma medical oncologyUniversity of texas md anderson cancer centerDivision of cancer medicineSarcoma unitRoyal marsdenSarcoma medical oncologyCancer medicineCancer centerGastrointestinal stromal tumorPeak trial